constructed an MLP deep learning model that distinguishes treatment responders from non-responders by combining multi-omics data from advanced NSCLC patients treated with PD-1/PD-L1 inhibitors, showing an excellent differentiated performance (165). Here, PDCD1 is linked to non-small cell lung carcinoma.